Trial Profile
Early Access of TMC114 in Combination With Low-Dose Ritonavir (TMC/r)) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to no Treatment Options.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Expanded access
- Sponsors Janssen R&D Ireland
- 26 Jan 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.